PRESS RELEASE published on 09/30/2026 at 00:37, 1 month 22 days ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2026, including revenue of €(1.2) million, highlighting successful manufacturing technology transfer and progress in clinical studies Revenue Clinical Studies GenSight Biologics Interim Financial Results Manufacturing Technology Transfer
BRIEF published on 09/08/2026 at 07:35, 2 months 13 days ago GenSight Biologics: Review and Outlook as of September 2026 GenSight Biologics Gene Therapies REVISED STUDY LUMEVOQ® Manufacturing Access Programs
PRESS RELEASE published on 09/08/2026 at 07:30, 2 months 13 days ago Inside Information / Other news releases GenSight Biologics provides business updates on manufacturing, clinical activities, and financial status for September 2026, including progress on gene therapy treatments Financial Updates Manufacturing Business Updates Clinical Activities GenSight Biologics
BRIEF published on 07/08/2026 at 19:16, 4 months 13 days ago GenSight Biologics presents its financial situation and therapeutic advances Treasury GenSight Biologics Phase III RECOVER Early Access GS010/LUMEVOQ®
BRIEF published on 07/08/2026 at 19:16, 4 months 13 days ago GenSight Biologics Announces Cash Position and Business Updates Cash Position Clinical Trials Business Updates Early Access Programs Manufacturing Process
PRESS RELEASE published on 07/08/2026 at 19:11, 4 months 13 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position updates as of June 30, 2026, along with business developments, including proceeds from early access programs and manufacturing process improvements Cash Position Business Updates GenSight Biologics Early Access Programs Manufacturing Process
BRIEF published on 04/28/2026 at 20:40, 6 months 23 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 6 months 23 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
PRESS RELEASE published on 04/28/2026 at 20:35, 6 months 23 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 7 months 14 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
Published on 11/20/2026 at 15:00, 1 day 12 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 12 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 13 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 3 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 6 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 8 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 8 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 9 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 10 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 8 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 19 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing